Megan Nakashima, MD
- Call 216.442.5636
Specialty in Diseases & Conditions
- Amyloidosis
- Chronic Eosinophilic Leukemia (CEL)
- Hairy Cell Leukemia
- Hypereosinophilic Syndromes
- IgM Monoclonal Gammopathy
- Lymphoplasmacytic Lymphoma
- Rare Cancer and Blood Disease Program
- Systemic Mastocytosis
- Waldenstrom’s Macroglobulinemia
Insurance
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.
View All PlansAbout Megan Nakashima, MD
Megan O. Nakashima, MD, is a Staff Hematopathologist and Hematopathology Fellowship Director in the Cleveland Clinic Pathology and Laboratory Medicine Institute. Dr. Nakashima received her undergraduate degree in Biology at Harvard University, followed by a medical degree at Washington University in St. Louis. She completed residency in Anatomic and Clinical Pathology at the Hospital of the University of Pennsylvania, followed by a fellowship in Selective (surgical) Pathology at Barnes-Jewish Hospital/Washington University of Medicine. She first came to Cleveland Clinic in 2012 for Hematopathology fellowship, then joined the staff in 2013.
Within hematopathology, Dr. Nakashima specializes in diseases of blood and bone marrow. She also performs consultations on the hemostasis service. Her research interests include plasma cell neoplasms and small B-cell lymphomas of the bone marrow, which relates to additional responsibilities in protein electrophoresis and amyloid typing. She is board certified in Anatomic and Clinical Pathology and Hematopathology.
Dr. Nakashima has an interest in laboratory quality and stewardship, which extends to her work as Medical Director of Automated Hematology and Urinalysis at main campus, Laboratory Director for several Family Health Center laboratories, and service on the Cleveland Clinic Laboratory Stewardship Committee, as well as committees in the College of American Pathologists and International Society for Laboratory Hematology. She is also an active member of several other national and international pathology and hematology societies. As Director of the Hematopathology Fellowship she is constantly engaged in the education of fellows and residents, and also enjoys producing other educational materials for a broader audience, online and in print.
Education & Professional Highlights
Appointed
2013
Education & Fellowships
Fellowship - Cleveland Clinic
Hematology (Pathology)
Cleveland,
OH USA
2013
Fellowship - Barnes-Jewish Hospital/Washington University School of Medicine
Selective Pathology
St. Louis,
MO USA
2012
Residency - Hospital of the University of Pennsylvania
Anatomic & Clinical Pathology
Philadelphia,
PA USA
2011
Medical Education - Washington University School of Medicine
M.D.
St. Louis,
MO USA
2007
Undergraduate - Harvard University
A.B.
Cambridge,
MA USA
2002
Certifications
- Pathology - Anatomic & Clinical Pathology
- Pathology - Hematopathology
Awards & Honors
- John Beach Hazard Awardfor Teaching, Cleveland Clinic, 2018
Research & Publications
See publications for Megan Nakashima, MD.
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/13/2023, Dr. Nakashima has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
